FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2904220679> ?p ?o ?g. }

• W2904220679 endingPage "4814" @default.
• W2904220679 startingPage "4814" @default.
• W2904220679 abstract "Abstract Introduction: MM pts have one of the highest risks of TE among cancer pts. Use of IMiDs plus dex further increases this risk. Guidelines recommend thromboprophylaxis based on risk assessment; however, limited large-scale studies have attempted to validate previous and identify new patient-specific risk factors associated with TE in MM pts. Methods: We conducted a retrospective review of 834 new or relapsed MM pts treated at Levine Cancer Institute between January 2012 to December 2017. Eligibility criteria for final analysis included age ≥ 18 years, diagnosis of MM, and treatment with thalidomide, lenalidomide or pomalidomide plus dex. Incidence of TE, including pulmonary embolism, deep vein thrombosis, and myocardial or cerebrovascular infarction, was documented up to 6 months after start of IMiD therapy. Presence of anticoagulation (AC)/antiplatelet therapy and type (aspirin [ASA], clopidogrel, low molecular weight heparin, warfarin, rivaroxaban, apixaban, dabigatran) were documented for each pt. Univariate and multivariable logistic regression models were used to investigate the association between TE incidence and race, gender, age, BMI, cytogenetic risk level, disease burden (bone marrow plasma cell percentage), AC/antiplatelet use, history of TE, and presence or history of comorbidities, including diabetes, kidney disease, atrial fibrillation, coronary artery disease, heart disease, and clotting disorder. Results: Of 834 pts, 373 were eligible for final analysis; 311 were excluded for not receiving an IMiD, 109 did not receive dex concomitantly with IMiD, and the remainder had other plasma cell dyscrasias and/or insufficient records. Mean age at IMiD start was 65.8 years; 48.5% were female, 58.2% Caucasian, and 35.4% African American. Most pts (96.5%) received lenalidomide as initial IMiD and 24% had high-risk disease. Half of all pts had ≥ 1 comorbidity, 8% had a history of TE, 73.7% received ASA prophylaxis, 14.2% received a stronger AC, and 12.1% did not receive thromboprophylaxis. The overall TE incidence was 31/373 (8.3%), of which 25 (6.7%) were venous and 6 (1.6%) were arterial. Of these, 30 received thromboprophylaxis. TE incidence among patients receiving ASA was 25/275 (21 venous, 4 arterial) and incidence among patients receiving stronger ACs was 5/53 (4 venous, 1 arterial). The univariate and multivariable results are summarized in the table. In univariate analysis, presence of ≥ 1 comorbidity (OR 2.98, 95% CI 1.30-6.84; p=0.01) and history of kidney disease (OR 2.65, 95% CI 1.25-5.62; p=0.01) were significantly associated with TE incidence; a trend was noted for higher TE risk in males (p=0.06). Presence of any comorbidity was the only covariate retained in the multivariable model (OR 2.82, 95% CI 1.22-6.57; p=0.016). TE incidence in pts with any comorbidity was 12% compared to 4.4% in those without any comorbidity (p=0.008). No other clinical factors were associated with TE incidence. Conclusion: In a large single-institution analysis, we identified that MM pts with ≥ 1 comorbidity had a significantly higher risk of TE. This is consistent with current guidelines that recommend use of at least ASA prophylaxis in this population with escalation to stronger AC in patients with more than one comorbidity. Of the comorbidities studied, kidney disease was the only one significant in univariate analysis. Unique to our study, we evaluated the association between disease burden and cytogenetic risk with TE incidence and identified no significant association. Also, prior studies suggest African Americans are at a higher TE risk, however, this was not the case in our population, which was comprised of at least one-third African Americans. Interestingly, while the goal of thromboprophylaxis is to decrease TE risk, there remained an 8.3% event rate with all but one of the patients prescribed prophylaxis when the event occurred. While compliance with thromboprophylaxis is difficult to quantify, this raises concern that ASA and some ACs may not be sufficient to ameliorate TE risk entirely. Adherence to current prophylaxis guidelines is critical, along with further prospective investigation into which ACs are most efficacious at preventing TE events, particularly in high risk pts. Table. Table. Disclosures Voorhees: Oncopeptides: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: served on an IRC; Amgen Inc.: Speakers Bureau; TeneoBio: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: served on an IRC; Novartis: Consultancy, Other: served on an IRC; Janssen: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Usmani:Abbvie, Amgen, Celgene, Genmab, Merck, MundiPharma, Janssen, Seattle Genetics: Consultancy; Amgen, BMS, Celgene, Janssen, Merck, Pharmacyclics,Sanofi, Seattle Genetics, Takeda: Research Funding." @default.
• W2904220679 created "2018-12-22" @default.
• W2904220679 creator A5009378735 @default.
• W2904220679 creator A5012295449 @default.
• W2904220679 creator A5017645198 @default.
• W2904220679 creator A5030373036 @default.
• W2904220679 creator A5041957821 @default.
• W2904220679 creator A5045179755 @default.
• W2904220679 creator A5059420792 @default.
• W2904220679 creator A5071438752 @default.
• W2904220679 creator A5080870057 @default.
• W2904220679 date "2018-11-29" @default.
• W2904220679 modified "2023-10-01" @default.
• W2904220679 title "Risk Factors for Thromboembolism (TE) in Multiple Myeloma (MM) Patients (pts) Treated with Immunomodulatory Agents (IMiDs) Plus Dexamethasone (dex)" @default.
• W2904220679 doi "https://doi.org/10.1182/blood-2018-99-118283" @default.
• W2904220679 hasPublicationYear "2018" @default.
• W2904220679 type Work @default.
• W2904220679 sameAs 2904220679 @default.
• W2904220679 citedByCount "0" @default.
• W2904220679 crossrefType "journal-article" @default.
• W2904220679 hasAuthorship W2904220679A5009378735 @default.
• W2904220679 hasAuthorship W2904220679A5012295449 @default.
• W2904220679 hasAuthorship W2904220679A5017645198 @default.
• W2904220679 hasAuthorship W2904220679A5030373036 @default.
• W2904220679 hasAuthorship W2904220679A5041957821 @default.
• W2904220679 hasAuthorship W2904220679A5045179755 @default.
• W2904220679 hasAuthorship W2904220679A5059420792 @default.
• W2904220679 hasAuthorship W2904220679A5071438752 @default.
• W2904220679 hasAuthorship W2904220679A5080870057 @default.
• W2904220679 hasConcept C126322002 @default.
• W2904220679 hasConcept C141071460 @default.
• W2904220679 hasConcept C2776063141 @default.
• W2904220679 hasConcept C2776301958 @default.
• W2904220679 hasConcept C2776364478 @default.
• W2904220679 hasConcept C2778524551 @default.
• W2904220679 hasConcept C2778661090 @default.
• W2904220679 hasConcept C2778810321 @default.
• W2904220679 hasConcept C2779161974 @default.
• W2904220679 hasConcept C2780638905 @default.
• W2904220679 hasConcept C71924100 @default.
• W2904220679 hasConceptScore W2904220679C126322002 @default.
• W2904220679 hasConceptScore W2904220679C141071460 @default.
• W2904220679 hasConceptScore W2904220679C2776063141 @default.
• W2904220679 hasConceptScore W2904220679C2776301958 @default.
• W2904220679 hasConceptScore W2904220679C2776364478 @default.
• W2904220679 hasConceptScore W2904220679C2778524551 @default.
• W2904220679 hasConceptScore W2904220679C2778661090 @default.
• W2904220679 hasConceptScore W2904220679C2778810321 @default.
• W2904220679 hasConceptScore W2904220679C2779161974 @default.
• W2904220679 hasConceptScore W2904220679C2780638905 @default.
• W2904220679 hasConceptScore W2904220679C71924100 @default.
• W2904220679 hasIssue "Supplement 1" @default.
• W2904220679 hasLocation W29042206791 @default.
• W2904220679 hasOpenAccess W2904220679 @default.
• W2904220679 hasPrimaryLocation W29042206791 @default.
• W2904220679 hasRelatedWork W1980555552 @default.
• W2904220679 hasRelatedWork W2160586820 @default.
• W2904220679 hasRelatedWork W2602745543 @default.
• W2904220679 hasRelatedWork W2789972226 @default.
• W2904220679 hasRelatedWork W2811048362 @default.
• W2904220679 hasRelatedWork W2904220679 @default.
• W2904220679 hasRelatedWork W2979968592 @default.
• W2904220679 hasRelatedWork W3107582387 @default.
• W2904220679 hasRelatedWork W3198203860 @default.
• W2904220679 hasRelatedWork W1570353559 @default.
• W2904220679 hasVolume "132" @default.
• W2904220679 isParatext "false" @default.
• W2904220679 isRetracted "false" @default.
• W2904220679 magId "2904220679" @default.
• W2904220679 workType "article" @default.